The analyst rating for WUXI BIO was upgraded due to better-than-expected revenue and adjusted net profit growth for 2025, which surpassed forecasts. The company's management also provided positive preliminary guidance for revenue growth this year, indicating potential for even higher growth when excluding foreign exchange impacts.
